Platinum Complexes
Recently Published Documents





2021 ◽  
Vol 10 (2) ◽  
pp. 26-35
Dien Luong Xuan

Many experimental data show that bulky substituents on the molecules enhance solubility, catalytic activity, and photophysical properties due to the prevention of π-π stacking in metal salicylaldimines. In order to understand the effect of bulkiness of substituents on the properties of the obtained molecules, the author researched and synthesized two new pyrene-based salicylaldiminato-type ligands that were substituted at 7-position and functionalized on imine group with bulky substituents. After the introduction of  the tert-butyl group at 7-position of pyrene by Friedel-Crafts reaction, the syntheses of new ligands 1-hydroxy-2-[((2,6-dimethylphenyl)-imino)methyl]-7-(tert-butyl)-pyrene 3, 2-hydroxy-1- [((2,6-dimethylphenyl)imino)methyl]-7-(tert-butyl)-pyrene 4 and corresponding platinum complexes 3(Pt), 4(Pt) were performed in the different ways with the synthetic processes of the complexes 1(Pt) and 2(Pt). The new ligands and complexes were characterized by 1H NMR, IR spectroscopy, mass spectroscopy, elemental analysis and X-ray diffraction, only for 3(Pt). In addition to measurements of the absorption and emission spectra, TDDFT calculations using the B3LYP functions were also performed. The complexes 3(Pt) and 4(Pt) exhibit good solubility and red-shift in absorption and emission spectra because of tert-butyl group at 7-position of pyrene and extension of the delocalized π-orbitals to the 2,6-dimethylphenyl on imine group. The change of functional groups also induces the upfield shift of the protons affected by ring currents of phenyl groups Ar-3, Ar-4 on imine groups. Introduction of t-butyl groups in pyrene moieties can stabilize radical forms in oxidation processes.

Rajiv Sharma ◽  
Vikram Jeet Singh ◽  
Pooja A Chawla

Background: The platinum (II) complexes as anticancer agents have been well explored for the development of novel analogs. Yet, none of them achieved clinical importance in oncology. At present, anticancer compounds containing platinum (II) complexes have been employed in the treatment of colorectal, lung, and genitourinary tumors. Among the platinum-based anticancer drugs, Cisplatin (cis-diamine dichloroplatinum (II), cis-[Pt(NH3)2Cl2]) is one of the most potent components of cancer chemotherapy. The nephrotoxicity, neurotoxicity and ototoxicity, and platinum compounds associated resistant cancer are some major disadvantages. Objective: With the rapidly growing interest in platinum (II) complexes in tumor chemotherapy, researchers have synthesized many new platinum analogs as anticancer agents that show better cytotoxicity, and less off-target effects with less cellular resistance. This follows the introduction of oxaliplatin, water-soluble carboplatin, multinuclear platinum and newly synthesized complexes, etc. Method: This review emphasizes recent advancements in drug design and development, the mechanism of platinum (II) complexes, their stereochemistry, current updates, and biomedical applications of platinum-based anticancer agents. Conclusion: In the last few decades, the popularity of platinum complexes as potent anti-cancer agents has risen as scientists have synthesized many new platinum complexes that exhibit better cytotoxicity coupled with less off-target effects.

Violeta Sicilia ◽  
Lorenzo Arnal ◽  
Daniel Escudero ◽  
Sara Fuertes ◽  
Antonio Martin

2021 ◽  
Vol 446 ◽  
pp. 214113
Alessia Colombo ◽  
Claudia Dragonetti ◽  
Véronique Guerchais ◽  
Dominique Roberto

Pablo Ríos ◽  
Francisco José Fernández de-Córdova ◽  
Javier Borge ◽  
Natalia Curado ◽  
Agustí Lledós ◽  

Sign in / Sign up

Export Citation Format

Share Document